2 results
Approved WMOCompleted
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72 hours and &…
Approved WMORecruiting
The project*s overarching aim is to diminish respiratory disease burden in moderate-late preterm born infants in their first year of life.We have formulated the following specific aims: 1. Determine whether bacterial lysates reduce the number and/or…